Cargando…
HSF1 is involved in immunotherapeutic response through regulating APOJ/STAT3-mediated PD-L1 expression in hepatocellular carcinoma
Hepatocellular cancer (HCC) is a serious illness with high prevalence and mortality throughout the whole world. For advanced HCC, immunotherapy is somewhat impactful and encouraging. Nevertheless, a substantial proportion of patients with advanced HCC are still unable to achieve a durable response,...
Autores principales: | Cheng, Hongxia, Wang, Sikai, Huang, Aidan, Ma, Jing, Gao, Dongmei, Li, Miaomiao, Chen, Huaping, Guo, Kun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746510/ https://www.ncbi.nlm.nih.gov/pubmed/36482717 http://dx.doi.org/10.1080/15384047.2022.2156242 |
Ejemplares similares
-
Effects of LRP1B Regulated by HSF1 on Lipid Metabolism in Hepatocellular Carcinoma
por: Li, Miaomiao, et al.
Publicado: (2020) -
Plasma Clusterin (ApoJ) Levels Are Associated with Adiposity and Systemic Inflammation
por: Won, Jong Chul, et al.
Publicado: (2014) -
Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer
por: Wang, Luyao, et al.
Publicado: (2023) -
Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors
por: Arbour, Kathryn C., et al.
Publicado: (2017) -
Accumulation of dysfunctional tumor-infiltrating PD-1+ DCs links PD-1/PD-L1 blockade immunotherapeutic response in cervical cancer
por: Wang, Yu-meng, et al.
Publicado: (2022)